MRKproduct launch
Merck & Co. has discontinued its clinical development program for the investigational drug nemtabrutinib following a safety review.
Benzinga
5 stories shown
Merck & Co. has discontinued its clinical development program for the investigational drug nemtabrutinib following a safety review.
Merck has announced a 3.5% increase in its quarterly dividend to $0.88 per share.
Analysts identify Eli Lilly, Roche, and Merck as attractive Big Pharma stocks, driven by raised guidance and long-term recovery prospects.
The FDA has reportedly halted its controversial fast-track drug review pilot program amid internal turmoil and a prolonged leadership vacuum.
Major pharmaceutical companies are investing billions in vaccines, including promising cancer and shingles vaccines, despite political hurdles.